Seres Therapeutics, Inc. products
Seres - Investigational, Oral, Biologically-Derived Microbiome Therapeutic Ulcerative Colitis
SER-287 is an investigational, oral, biologically-derived microbiome therapeutic for the treatment of ulcerative colitis (UC). SER-287 is a consortium of multiple bacterial spores manufactured by fractionating and purifying targeted bacteria from stool of healthy human donors. SER-287 has been granted Fast Track designation and Orphan Drug designation by the FDA. A completed SER-287 Phase 1b clinical study demonstrated a statistically significant difference in the clinical remission rate between patients with active mild-to-moderate ulcerative colitis treated with vancomycin followed by daily SER-287 for 8 weeks compared to the placebo group, and a favorable safety profile.
Seres - Investigational, Oral, Rationally-Designed, Fermented Microbiome Therapeutic Ulcerative Colitis
SER-301 is an investigational, oral, rationally-designed, fermented microbiome therapeutic for the treatment of mild-to-moderate ulcerative colitis (UC). SER-301 is a consortium of multiple bacterial strains that is manufactured by fermenting each strain individually and then combining to form drug product.
Seres - Investigational, Oral, Rationally Designed, Fermented Microbiome Therapeutic
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Seres - First-In-Class Investigational Microbiome Therapeutic
SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent CDI.